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Introduction
Leiomyosarcomas (LMS) are relatively uncommon
and account for 7% of soft tissue sarcomas (STS).
Just as their benign counterparts, leiomyomas (LM),
they show differentiation towards smooth muscle.1
Few studies have focused exclusively on this rare type
of tumor. In STS, tumor grade is considered to be
the most signi￿ cant prognostic factor, the two most
important parameters being the number of mitotic
￿ gures and the extent of necrosis.1Various studies2–5
examined the prognostic value of other parameters,
such as DNA ploidy, Ki-67 (a monoclonal antibody,
which reacts with a nuclear antigen expressed in all
phases of the cell cycle except G0), and apoptosis, in
heterogeneous groups of STS patients.Overall,aneu-
ploidy, a high amount of Ki-67, and low frequencies
of  apoptotic  cells  seem  to  be  related  to  a  worse 
clinical outcome in patients with different types of
STS. The  signi￿ cance  of  the  above-mentioned 
parameters  may  differ  among  various  histological
types of STS, which may be the reason for inconsis-
tent  results  between  different  studies. 6,7 Studies
focusing exclusively on LMS,express the signi￿ cance
of  the site of the tumor on its behaviour, i.e., the
prognosis of patients  with (sub)cutaneous LMS is
better  than  that  of  patients  with  deep-seated 
LMS, despite their  similar  histological  and  tumor
biological features.1,8–11  Jensen et al. recommended
that  super￿ cial  LMS  be  separated  further  into 
lesions  with  predominant  cutaneous  growth  and
tumors  that  involve  the  subcutis, since  cutaneous
LMS  generally  have  a  better  prognosis, and  only
tumors involving the subcutis have the tendency to
metastasize.1,10–13 
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Abstract
Purpose: Leiomyosarcomas (LMS) of deep and super￿ cial tissues were examined to identify prognostic markers explaining
their different biological behaviour and to de￿ ne differences between cutaneous and subcutaneous LMS. LMS and leiomy-
omas (LM) of the skin were compared to ￿ nd consistent differences that could aid in the (sometimes dif￿ cult) diagnosis.
Patients: Material was obtained from 27 patients with a deep LMS, 14 with a super￿ cial LMS, and 21 with a LM.
Methods: Proliferation markers (mitotic and Ki-67 indices), DNA ploidy, size, grade, and the amount of apoptosis were
studied.Statistical analysis was performed and survival curves were constructed by the Kaplan-Meier method and compared
by the log-rank test.
Results:Super￿ cial LMS were smaller than deep LMS (p < 0.05), and the overall survival of patients with a super￿ cial LMS
was better than with a deep LMS (p < 0.05).Within the group of super￿ cial LMS only entirely subcutaneous, and not cuta-
neous tumors metastasized.No differences were found in the other examined parameters.Proliferation and apoptotic indices
were signi￿ cantly higher in super￿ cial LMS compared to super￿ cial LM.
Discussion: The difference in clinical outcome between patients with a super￿ cial and deep LMS, seems to be related to site
and size.The metastatic potential of subcutaneous LMS, however, seems to be related to location alone and not to size.The
amount of apoptosis and proliferation can be used as additional criteria in the differentiation between super￿ cial LMS and
LM.
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DOI: 10.1080/1357714021000065404In  the  diagnosis  of  smooth  muscle  tumors, the
distinction between malignant and benign may be
dif￿ cult.1 Factors  which  discriminate  most  in  the
clinical differential diagnosis are tumor size and loca-
tion, benign tumors usually being small and located
super￿ cially.14  To  date, no  study  has  compared
(sub)cutaneous LMS with (sub)cutaneous LM.
The aim of this study is to ￿ nd possible differences
between LMS of deep soft tissue (excluding gastro-
intestinal  stromal  tumors  and  urogenital  tumors),
subcutaneous  and  cutaneous tissue, and  to  deter-
mine  whether  proliferation  markers  (mitotic  and 
Ki-67  indices), size, grade, DNA  ploidy  and  the
amount of apoptosis correlate with the differences in
their  biological  and  clinical  behaviour. We  also
analysed differences between LMS and LM of the
cutis and subcutis, in order to ￿ nd new diagnostic
criteria.
Patients
We collected all available material of all patients diag-
nosed between  1980  and  1998  with  a  LMS  or  a
super￿ cial  LM  in  the  northern  region  of  The
Netherlands. Material of 16 patients with super￿ cial
LM(S) was donated by the Department of Derma-
topathology, Fachklinik Hornheide in Germany.The
diagnosis was based on the criteria of Enzinger and
Weiss,1 using light microscopic examination of hema-
toxylin-eosin  (HE)-stained  paraf￿ n  sections, and,
when  necessary, the  diagnosis  was  con￿ rmed
immunohistochemically  using  antibodies  to  actin
and desmin. A total of 62 patients were included in
the present study.
Material  was  obtained  from  27  patients  with  a
primary  LMS  of  deep  soft  tissue (Table  1). The
median age  was  60  (range  20–83)  years. Thirteen
patients  had  extremity  tumors, whereas  three
patients had a retroperitoneal LMS.
Fourteen patients with a super￿ cial LMS (Table 1)
were included in this study.The median age was 62
(range  23–85)  years. Three  patients  had  a  tumor
con￿ ned to the cutis, whereas seven patients had a
super￿ cial  LMS  involving  both  the  cutis  and  the
subcutis. The remaining four patients had a tumor
con￿ ned to the subcutis.
Twenty-one patients with a super￿ cial LM (Table
1) were analysed. Except  for one, all tumors were
con￿ ned to  the  cutis, so no distinction was  made
between  cutaneous  or  subcutaneous  tumors. The
median age was 56 (range 7–83) years. A tumor was
considered a LM, when no mitoses were found.
The patient records were used to collect the clin-
ical data. Overall survival (OS) and survival status
(NED, no  evidence  of  disease; AWD, alive  with
disease; DOD, died of disease; DOC, died of other
causes; LOF, lost to follow-up) were recorded for the
patients  with  a  deep  and  super￿ cial  LMS.
Recurrence and metastatic disease were recorded as
well (Table 1).
Methods
Grading
The  LMS  were  graded  according  to  the  system
described by  Coindre et  al.,15 in which  points are
assigned to differentiation level (1,closely resembling
normal tissue;2, certain histogenetic classi￿ cation;3,
undifferentiated), mitotic index per 2 mm2 (1, 0–9;
2, 10–19;3, 20 or more) and necrosis (0,none;1, less
than 50%; 2, more than 50%). Tumors with a total
score of 2 or 3 were graded as grade I, those with a
total score of 4 or 5 as grade II and those with a total
score of 6–8 as grade III.
DNA ploidy
DNA ￿ ow cytometry was performed on single cell
suspensions obtained from formalin-￿ xed  paraf￿ n-
embedded  tissue  or  fresh  tissue, as  previously
described  by  Plaat  et  al.6 The  DNA  pro￿ le  was
considered (near)diploid when a single stem line was
present in the diploid range; all others were consid-
ered aneuploid.
Proliferation and apoptosis
For proliferation, the monoclonal antibody MIB 1,
which  recognizes  the  Ki-67  antigen, was  used
(Immunotech  S.A., Marseille, France). Immuno-
histochemistry was performed on paraf￿ n sections 
(4 µm)  according to a  method modi￿ ed from Shi 
et al.16,17
Apoptosis  was  studied  in  4-µm  sections  of
formaldehyde-￿ xed  and  paraf￿ n-embedded  tissue
using the TUNEL (terminal deoxynucleotidyl trans-
ferase  (TdT)  mediated  dUTP  nick  end  labeling)
method, as previously described by Plaat et al.18
Quanti￿ cation of Ki-67 and apoptosis
For  measuring  the  Ki-67  labeling  index  and  the
apoptotic labeling index we used ocular micrometry
on a Leitz microscope by using an eyepiece grid at
´400  magni￿ cation. Fifteen  ￿ elds  were  randomly
selected throughout histologically  viable areas. The
positive  and  negative  nuclei  were  counted.
Endothelial  cells, in￿ ammatory  cells  and  necrosis
were excluded. The number of positive nuclei was
then divided by the total number of nuclei in each of
the ￿ fteen randomly selected ￿ elds to calculate an
index per ￿ eld.The Ki-67 and the apoptotic indices
were de￿ ned as the mean of the indices of the 15
randomly selected ￿ elds.
Statistical analysis
To  compare  OS  and  survival  status  in  relation  to
grade, size, DNA ploidy, and Ki-67 and apoptotic
indices, survival  curves  were  constructed  by  the
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ent groups were compared by the log-rank test. A 
m 2-test or m 2-test for trend was used to estimate the
differences in tumor grade and DNA ploidy.A Mann-
Whitney U-test was used to analyse the differences
between  proliferation  markers  (mitoses, Ki-67),
apoptosis and size in the different groups. A p value
of  <0.05 was considered statistically signi￿ cant.
Results
The results of the different groups are shown in Table
2. Due  to  technical failures  and in some cases to
insuf￿ cient  material, not  all  tumors  could  be
analysed for Ki-67 and apoptotic indices, grading, or
DNA  ploidy. By  analyzing  the  total  group  of  41
patients with a LMS, no signi￿ cant correlations were
found between OS and mitotic, Ki-67 indices, apop-
totic indices, grade, or DNA ploidy (Table 2).
Deep versus super￿ cial LMS
Patients with a super￿ cial LMS had a signi￿ cantly
better OS compared to patients with a deep LMS
(Fig.1). More than half of all patients with a deep
LMS died of the tumor (52%). This is in contrast
with super￿ cial LMS,where none of the patients died
of  the  tumor. No  differences were found between
deep and super￿ cial LMS for mitotic,Ki-67 or apop-
totic indices, nor for grade and DNA ploidy (Table
2). Super￿ cial LMS had a signi￿ cantly (p = 0.001)
smaller size than deep LMS; 2.5 vs. 9.5 cm (Fig. 2).
Cutaneous versus subcutaneous LMS
Of the 14 super￿ cial LMS,three tumors were limited
to the cutis, four to the subcutis, and seven tumors
involved both the cutis and the subcutis (Table 1).
None of the three entirely cutaneous LMS metasta-
sized,whereas three of the four subcutaneous tumors
metastasized. None of the seven cutaneous/subcuta-
neous tumors metastasized, although  two  of  them
showed  a  local  recurrence (p > 0.5). No  statistical
differences were found between mitotic, Ki-67 and
apoptotic indices, grade, and DNA ploidy between
the three groups (Table 2).
Super￿ cial LM versus super￿ cial LMS
The  super￿ cial  LMS  had  a  mean  Ki-67  index  of
8.4% and a mean apoptotic index of 0.33%. In the
LM this was 1.0 and 0.01%, respectively (p < 0.005)
(Figs. 3 and 4). Two super￿ cial LMS were diploid,
two  were  aneuploid. All  of  the  LM  were  diploid 
(p = 0.19).
Discussion
The signi￿ cance of various prognostic factors, such
as  DNA ploidy, Ki-67  and apoptotic  indices, may
differ among various types of STS.2–7 Most studies
include  only  a  few  smooth  muscle  tumors, or
compare different types, so that interpretation of the
results is not always easy. LMS is a rare tumor, and
its  behaviour  seems  to  depend  on  the  site  of  the
tumor.8–11 Therefore we studied LMS of deep and
super￿ cial tissue as one group to identify site-inde-
pendent prognostic markers, which could explain the
differences in biological behaviour. LMS and LM of
the skin were also compared to ￿ nd consistent differ-
ences that could aid in the differential diagnosis of
malignant  and  benign  super￿ cial  smooth  muscle
tumors.
Forty-one patients with a deep or super￿ cial LMS
were analysed in order to ￿ nd factors that could pre-
dict  clinical outcome. Although  studies examining
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Table 1. Patients with deep seated LMS,super￿ cial LMS and LM (62 patients)
Location N Age Sex Metastasis/ Follow-up (whole group)
(years) Local recurrence (status and duration)
Deep LMS 27 20–83  11 M/16F 9 NED (median: 33 months)
(median: 60) 3 AWD (median: 23 months)
Retroperitoneal 3 2 Metastases 14 DOD (median: 39 months)
Extremities 13 5 Metastases, 1 DOC (151 months)
2 local recurrences, 1?
Other 9 3 Metastases,
1 local recurrence, 2?
Super￿ cial LMS 14 23–85  9 M/5F 11 NED (median: 26 months)
(median: 62) 2 AWD (median: 18 months)
Cutaneous 3 No 1 LOF
Cutaneous/ 7 2 local recurrences
subcutaneous
Subcutaneous 4 3 Metastases
Super￿ cial LM 21 7–83  8 M/13F None N.A.
(median: 56)
(M, male; F, female; N.A., not available; NED, no evidence of disease;AWD, alive with disease; DOD, died of disease; DOC, died of other
cause; LOF, lost to follow-up; ?, unknown)large groups of heterogeneous STS showed a relation
between a high Ki-67  index and malignancy,2 low
apoptotic index and low grade,3 and aneuploidy and
bad prognosis,4,5 we did not con￿ rm any of these ￿ nd-
ings. This is similar to the ￿ ndings of Gustafson et
al.,19 who did not ￿ nd any relationship between DNA
ploidy and prognosis either. Although in our study
patients  with a high-grade  LMS did have a worse
prognosis, this was not statistically signi￿ cant, which
may be due to the limited number of LMS studied.
The  prognosis of  the  patients  with  a  super￿ cial
LMS was  signi￿ cantly  better  than  that  of  patients
with a deep LMS, which is in agreement with other
studies.1,8 We  found  no  difference  in  proliferation
markers (Ki-67  and mitotic indices), DNA  ploidy
and the amount of apoptosis. In a previous study,
deep  seated  LMS  with  a  high  amount  of  Ki-67
tended to have a worse prognosis, but this was also
not signi￿ cant.8 Although there seems to be a differ-
ence in grade between the two groups,i.e.deep LMS
showing  more  high-grade  tumors  than  super￿ cial
LMS (27 against 8%),this was not statistically signif-
icant.The different biological behaviour of these two
types of tumors, seems to be only associated with
their different locations.This is similar to a previous
study, where LMS in super￿ cial and deep soft tissues
were almost the same with regard to cell proliferation
and alteration of the p53 gene.8 However, we found
a signi￿ cantly different size between the two groups
(deep  LMS  being  larger  than  super￿ cial  LMS),
which also could explain the different outcome. It
seems  plausible  that  super￿ cial  LMS  are  earlier
discovered, so  that  their  growth  is  limited. The
conclusion is that the different outcome seems to be
related  only  to  the  location  and  size, the  latter 
probably being the most important.
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Table 2. Results of all LMS,deep LMS, super￿ cial LMS and LM
All LMS Deep LMS Super￿ cial leiomyoma Deep vs Super￿ cial
(41)* (27)* MS (14)* (21)* super￿ cial LMS vs LM
LMS
Grade (n): p > 0.05 –
I 13 (34%) 8 (31%) 5 (42%) –
II 17 (45%) 11 (42%) 6 (50%) –
III 8 (21%) 7 (27%) 1 (8%) –
Size (cm) p = 0.001 –
n 34 23 11 –
Range 0.05–30 2.0–30.0 0.5–11
Mean; median 8; 7.0 10; 9.5 3.6; 2.5
Mitotic index p > 0.05 –
(number of 
mitoses per
2 mm2
n 38 26 12
Range 0–44 1–44 0–25
Mean; median 12; 9 13; 9 9; 8
Ki-67 index (%) p > 0.05 p < 0.005
n 37 24 13 18
Range 0.60–36.8 0.8–36.8 0.6–20.2 0.4–1.9
Mean; median 10.4; 9.2 11.5; 9.7 8.4; 8.1 1.0; 0.9
Apoptotic  p > 0.05 p < 0.005
index (%)
n 36 23 13 17
Range 0.00–1.27 0.02–1.27 0.00–0.84 0.00–012
Mean; median 0.41; 0.32 0.46; 0.41 0.33; 0.27 0.01; 0.00
Diploid/ 8 (42%)/ 7 (44%)/ 1 (33%)/ 5 (100%)/0 p > 0.05 p > 0.05
aneuploid 11 (58%) 9 (56%) 2 (67%)
(% of 
analysed cases)
OS-time (months) p > 0.05 –
n = 40 27 13 –
Range 4–151 4–151 5–101
Mean; median 43; 27 47; 38 35; 23
Died of tumor 14 (35%) 14 (52%) 0 0 p < 0.005
*Due to technical failures. not all tumors could be analysed for Ki-67 amd apoptotic indices, grading or DNA ploidy.Within the group of super￿ cial LMS, site seems
also to be of importance in cutaneous and subcuta-
neous  tumors, as  they  have  a  different  prognosis.
Tumors con￿ ned to the cutis seem to have a better
clinical  outcome.1,10,11 Identifying  patients  with  a
greater risk of metastasis is important to determine
the prognosis or therapy. In agreement with other
studies,11–13 only  tumors  con￿ ned  to  the  subcutis
metastasized. We  found that  patients  with  a  LMS
con￿ ned  to  the  cutis, did  not  show  metastasis  or
recurrences. Proliferation  and  apoptosis  did  not
predict metastatic potential in super￿ cial LMS, nor
did any  of  the  other parameters. Although  in one
study only patients with diploid super￿ cial LMS had
metastases,20 we did not ￿ nd any relation between
malignancy  and  DNA  ploidy. Analyses  of  larger
groups maybe necessary to examine the relevance of
DNA  ploidy. The  impaired  prognosis  might  be
related to location alone, contrary to deep and super-
￿ cial LMS where size may also be of importance.
Patients with a tumor involving both the cutis and the
subcutis did not metastasize,but some of the patients
had a local recurrence. It seems that this last group
is  of  dermal origin, with  invasion of  the  subcutis.
Only tumors arising in the subcutis tend to metasta-
size; whether these two groups are different must be
further  examined. One  explanation  might  be  the
difference in origin; the cutaneous LMS are usually
arising from pilar arecti, and subcutaneous LMS are
mostly from vascular origin.21
As mentioned above, differentiation between LM
and LMS may be dif￿ cult. In rare cases, diagnosis
can be hard, imposing dif￿ culties upon the choice of
the right therapy and expected clinical behaviour.1 In
agreement  with  one  previous  study,22 comparing
different types of LM and LMS,the amount of apop-
tosis and proliferation were signi￿ cantly higher in the
super￿ cial  LMS  compared  to  the  LM. This  is  in
contrast  with  another  study,3 describing heteroge-
neous groups of STS, where less apoptosis is asso-
ciated with a worse outcome. This suggests a type-
speci￿ c  phenomenon. Apoptosis  and  proliferation
can be used as additional criteria in the differentia-
tion between LMS and LM of the skin. DNA ploidy
may also be of diagnostic importance, all of the LM
being diploid,but this should be con￿ rmed in a larger
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Fig. 1. Overall survival curve: deep and super￿ cial leiomyo-
sarcoma  (LMS). Solid  line, super￿ cial  LMS; dotted  line,
deep LMS. p < 0.05.
Fig. 2. Deep and  super￿ cial  leiomyosarcoma  (LMS): size.
p = 0.001.
Fig. 3. Leiomyoma  (LM)  and  super￿ cial  leiomyosarcoma
(LMS): Ki-67 indices. p < 0.005.
Fig. 4. Leiomyoma  (LM)  and  super￿ cial  leiomyosarcoma
(LMS): apoptotic indices. p < 0.005.series of tumor samples. It may be possible that these
results also  apply  to other types  of malignant and
benign smooth muscle tumors, and might aid in the
diagnosis of dif￿ cult cases.
In  summary, our  study  shows  that  the  clinical
behaviour  of  different  types  of  LMS  seems  to  be
related to the site of the tumor alone. The smaller
tumor  size  in  patients  with  a  super￿ cial  LMS,
compared  to  deep, is  probably  due  to  the  early
discovery of this kind of LMS, and may also be the
main reason for the better clinical outcome of these
patients.The reason why subcutaneous LMS have a
worse prognosis than entirely cutaneous LMS is not
yet clear, but might be related to the tumor origin.
Further examination is necessary to ￿ nd out of these
types of LMS have  a  different oncogenesis, which
may account for their different behaviour.Dif￿ culties
in the diagnosis between super￿ cial LMS and LM,
can be facilitated by determination of the amount of
apoptosis and proliferation.
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